Double-blind crossover trial shows improved flow rates and reduced obstructive symptoms in men with benign prostatic obstruction, suggesting prazosin is an effective therapeutic alternative.
Prazosin, a selective alpha-1-adrenoceptor blocker, was used in a double-blind crossover study in 20 men with benign prostatic obstruction. Maximum and average flow rates increased, and residual volume and obstructive symptoms were reduced. Voiding pressure parameters, bladder capacity and irritative symptoms did not change significantly. No side effects were noted. We conclude that prazosin seems to be an effective therapeutic alternative in patients with benign prostatic obstruction.
No takes yet. Share an insight, caveat, or question.
Hedlund et al. (1983) studied this question.
Synapse has enriched 4 closely related papers on similar clinical questions. Consider them for comparative context: